Results 171 to 180 of about 127,473 (347)

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Emerging maps of allosteric regulation in cellular networks. [PDF]

open access: yesCurr Opin Struct Biol, 2023
Mathy CJP, Kortemme T.
europepmc   +1 more source

Computational modelling of myocardial metabolism in patients with advanced heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction. Abstract Aims Perturbations of myocardial metabolism and energy depletion are well‐established hallmarks of heart failure (HF), yet methods for their systematic assessment remain limited in humans.
Niklas Beyhoff   +17 more
wiley   +1 more source

Identification of Regions of the Tomato γ-Glutamyl Kinase That Are Involved in Allosteric Regulation by Proline [PDF]

open access: hybrid, 2003
Tomomichi Fujita   +5 more
openalex   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

open access: yesEpilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang   +3 more
wiley   +1 more source

Allosteric regulation and inhibition of protein kinases. [PDF]

open access: yesBiochem Soc Trans, 2023
Mingione VR   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy